DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/74q7w8/human) has announced the addition of Global Markets Direct's new report "Human Papillomavirus Infections - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Human Papillomavirus Infections - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections.
Scope
- A snapshot of the global therapeutic scenario for Human Papillomavirus Infections.
- A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Human Papillomavirus Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- News and deals relating to the products.
Reasons to Buy
- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/74q7w8/human
Source: Global Markets Direct
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases
Source: Research and Markets